Trials / Active Not Recruiting
Active Not RecruitingNCT04204616
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemolizumab | Nemolizumab 30 mg will be administered as subcutaneous (SC) injection. |
Timeline
- Start date
- 2021-01-11
- Primary completion
- 2026-10-26
- Completion
- 2026-10-26
- First posted
- 2019-12-19
- Last updated
- 2025-11-12
Locations
164 sites across 16 countries: United States, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, South Korea, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04204616. Inclusion in this directory is not an endorsement.